Trials / Completed
CompletedNCT00230828
Patient-reported Outcomes in the Treatment of Schizophrenia
Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bifeprunox |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-01-01
- First posted
- 2005-10-03
- Last updated
- 2013-09-12
Source: ClinicalTrials.gov record NCT00230828. Inclusion in this directory is not an endorsement.